MAYNE PHARMA GROUP LIMITED — Director's Dealing 2011

Jan 19, 2011

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity	Mayne Pharma Group Limited
ABN	76 115 832 963

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Bruce Mathieson
Date of last notice	1 December 2010

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct and Indirect interest
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	1) Mr Bruce Mathieson 2) Mrs Jill Mathieson 3) Investment Holdings Pty Ltd 4) BLM Superannuation Nominees Pty Ltd
Date of change	19 January 2010
No. of securities held prior to change	261,622 Ordinary Fully Paid Shares (2) 10,298,378 Ordinary Fully Paid Shares (3) 1,101,622 Ordinary Fully Paid Shares (4) 250,000 Unlisted options for ordinary shares @ 60 cents expiring 17 April 2011 (1) 350,000 Unlisted options for ordinary shares @ 27 cents expiring 31 December 2012 (3)
Class	Ordinary fully paid shares (3)
Number acquired	1,500,000 (3)

• See chapter 19 for defined terms.

Appendix 3Y Page 1

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	$1,095,000 (3)
No. of securities held after change	261,622 Ordinary Fully Paid Shares (2) 11,798,378 Ordinary Fully Paid Shares (3) 1,101,622 Ordinary Fully Paid Shares (4) 250,000 Unlisted options for ordinary shares @ 60 cents expiring 17 April 2011 (1) 350,000 Unlisted options for ordinary shares @ 27 cents expiring 31 December 2012 (3)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Off market purchase of shares from Dr Roger Aston

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract Nature of interest Name of registered holder (if issued securities) Date of change No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired Interest disposed Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation Interest after change

• See chapter 19 for defined terms.

Appendix 3Y Page 2

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity	Mayne Pharma Group Limited
ABN	76 115 832 963

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Roger Aston
Date of last notice	5 November 2009

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct interest
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Direct interest (1) Newtonmore Biosciences Pty Ltd (2) Newtonmore Super Fund (3)
Date of change	19 January 2011
No. of securities held prior to change	5,320,000 Ordinary Shares (1) 4,251,000 Ordinary Shares (2) 1,000,000 Ordinary Shares (3) 625,000 Unlisted options for ordinary shares @ 60 cents expiring 17 April 2011 (1) 625,000 Unlisted options for ordinary shares @ 60 cents expiring 17 April 2012 (1) 1,900,000 Unlisted options for ordinary shares @ 27 cents expiring 31 December 2012 (1)
Class	Ordinary fully paid shares (1) Unlisted options for ordinary shares @ 60 cents expiring 17 April 2011 (2)

• See chapter 19 for defined terms.

Appendix 3Y Page 1

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

Number acquired	Nil
Number disposed	1,500,000 (1) 600,000 (2)
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	$1,095,000 (1) $90,000 (2)
No. of securities held after change	3,820,000 Ordinary Shares (1) 4,251,000 Ordinary Shares (2) 1,000,000 Ordinary Shares (3) 25,000 Unlisted options for ordinary shares @ 60 cents expiring 17 April 2011 (1) 625,000 Unlisted options for ordinary shares @ 60 cents expiring 17 April 2012 (1) 1,900,000 Unlisted options for ordinary shares @ 27 cents expiring 31 December 2012 (1)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Off market sale of shares to Mr Bruce Mathieson (1) Off market sale of options (2)

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract Nature of interest Name of registered holder (if issued securities) Date of change No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired Interest disposed Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation

• See chapter 19 for defined terms.

Appendix 3Y Page 2

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

Interest after change

• See chapter 19 for defined terms.

Appendix 3Y Page 3

11/3/2002